[Capecitabine in colorectal carcinoma: news from ASCO 2008]].
Longo
Flavia
F
Oncologia Medica A, Policlinico Umberto I, Roma.
Mansueto
Giovanni
G
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D015201:Meta-Analysis as Topic; D010071:Oxaloacetates; D016019:Survival Analysis
D000964:Antimetabolites, Antineoplastic; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil